NK-1 Receptor Antagonists: Blocking Substance P for Pain, Nausea, Depression, and Inflammation
NK-1 receptor antagonists (substance P blockers) represent a new pharmacological paradigm with applications in emesis (aprepitant approved), pain, depression, and inflammatory conditions — multi-indication potential.
Quick Facts
What This Study Found
NK-1 receptor antagonists (substance P blockers) represent a new pharmacological paradigm with applications in emesis (aprepitant approved), pain, depression, and inflammatory conditions — multi-indication potential.
Key Numbers
How They Did This
research study.
Why This Research Matters
Relevant for peptide research.
The Bigger Picture
Advances peptide research.
What This Study Doesn't Tell Us
See abstract.
Questions This Raises
- ?Further research needed.
Trust & Context
- Key Stat:
- Key finding NK-1 receptor antagonists (substance P blockers) represent a new pharmacological paradigm with applications in emesis (aprepitant approved), pain, dep
- Evidence Grade:
- emerging evidence.
- Study Age:
- Published in 2011.
- Original Title:
- NK-1 receptor antagonists: a new paradigm in pharmacological therapy.
- Published In:
- Current medicinal chemistry, 18(12), 1820-31 (2011)
- Authors:
- Muñoz, M, Coveñas, R
- Database ID:
- RPEP-01821
Evidence Hierarchy
Frequently Asked Questions
What was studied?
NK-1 Receptor Antagonists: Blocking Substance P for Pain, Nausea, Depression, and Inflammation
What was found?
NK-1 receptor antagonists (substance P blockers) represent a new pharmacological paradigm with applications in emesis (aprepitant approved), pain, depression, and inflammatory conditions — multi-indication potential.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-01821APA
Muñoz, M; Coveñas, R. (2011). NK-1 receptor antagonists: a new paradigm in pharmacological therapy.. Current medicinal chemistry, 18(12), 1820-31.
MLA
Muñoz, M, et al. "NK-1 receptor antagonists: a new paradigm in pharmacological therapy.." Current medicinal chemistry, 2011.
RethinkPeptides
RethinkPeptides Research Database. "NK-1 receptor antagonists: a new paradigm in pharmacological..." RPEP-01821. Retrieved from https://rethinkpeptides.com/research/munoz-2011-nk1-receptor-antagonists-a
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.